One email when the decision is public, with what it means in plain language. You'll also get new trials and FDA news for Duchenne Muscular Dystrophy. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
The FDA is expected to decide on Amondys 45 + Vyondys 53 for Duchenne muscular dystrophy (conversion to traditional approval) by February 28, 2027, under a sNDA from Sarepta Therapeutics.
What the FDA is deciding on Amondys 45 + Vyondys 53 for Duchenne muscular dystrophy
The FDA is reviewing Sarepta Therapeutics' request to update the label of Amondys 45 + Vyondys 53 for duchenne muscular dystrophy (conversion to traditional approval).
Sarepta asked the FDA to convert the accelerated approvals of Amondys 45 and Vyondys 53 to traditional approvals, citing its ESSENCE confirmatory study and real-world evidence. ESSENCE, which enrolled boys aged 6 to 13, did not show a statistically significant benefit on its main goal, how fast they climbed 4 stairs at 96 weeks, BioPharma Dive reported on November 4, 2025.
Sarepta said the study was compromised by the COVID-19 pandemic. Sarepta announced on June 30, 2026 that the FDA accepted both applications. Both drugs stay available under their accelerated approvals during the review.
Who the Amondys 45 + Vyondys 53 decision matters to
Duchenne muscular dystrophy is an X-linked genetic disorder causing progressive muscle weakness and degeneration, beginning in early childhood. The defective dystrophin protein normally protects muscle fibers from damage.
Without it, muscles deteriorate and are gradually replaced by fat and scar tissue. Multiple exon-skipping therapies (eteplirsen, golodirsen, viltolarsen, casimersen) are FDA-approved.
More about Duchenne Muscular Dystrophy
Delandistrogene moxeparvovec (Elevidys), the first gene therapy for DMD, received accelerated FDA approval in June 2023. In June 2024 the FDA granted traditional approval for ambulatory patients (those who can walk) aged 4 and older and accelerated approval for non-ambulatory patients.
After 2 deaths from acute liver failure in non-ambulatory patients, the FDA announced an investigation in June 2025, and in July 2025 it asked Sarepta to pause all shipments; on July 28, 2025 it recommended that treatment of ambulatory patients resume. In November 2025, the FDA added a boxed warning (its most serious warning) for acute serious liver injury and acute liver failure, including deaths, and limited the indication to ambulatory patients aged 4 and older, so Elevidys is no longer approved for non-ambulatory patients.
Prevalence: 1 in 3,500 to 5,000 male births. See our full Duchenne Muscular Dystrophy page for current treatments, recruiting trials, and community resources.
What an approval or a rejection of Amondys 45 + Vyondys 53 would mean
Amondys 45 + Vyondys 53 is already sold in the US for Duchenne Muscular Dystrophy, so an approval changes its label rather than whether families can get it.
A complete response letter would mean the FDA declined to approve in the application's current form. The letter describes what the FDA wants addressed, and the company then decides whether to resubmit, run more studies or stop. Either way, this page updates with the outcome and what it means.
Where Duchenne Muscular Dystrophy treatment stands today
Read our full Duchenne Muscular Dystrophy treatment summary
DMD research is remarkably active, with multiple exon-skipping therapies approved or in advanced trials, offering hope for slowing or stabilizing disease progression.
Two newer oral medicines are FDA approved for DMD regardless of the specific mutation: vamorolone (Agamree), a once-daily corticosteroid liquid approved in October 2023 for patients 2 years and older, and givinostat (Duvyzat), a twice-daily histone deacetylase (HDAC) inhibitor liquid that targets inflammation and muscle loss, approved in March 2024 for patients 6 years and older.
Gene therapy approaches are expanding, and newer antisense oligonucleotides are being tested for additional dystrophin mutations. The Muscular Dystrophy Association maintains a comprehensive trial database.
These advances are most impactful when started early, so if you have a recently diagnosed child, discuss with your neurologist which newer therapies might be appropriate and monitor emerging trial opportunities.
Genetic testing to identify your specific dystrophin mutation can help determine which targeted therapies you're eligible for.
The Duchenne Muscular Dystrophy page has every treatment and trial →Meanwhile, 79 Duchenne Muscular Dystrophy studies are open or about to open
Whatever the FDA decides here, research on Duchenne Muscular Dystrophy does not stop. The most recently updated:
We'll email you when the decision is public, with what it means in plain language, and when new trials open for Duchenne Muscular Dystrophy. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Frequently asked questions
When will the FDA decide on Amondys 45 + Vyondys 53?
The FDA's target date (PDUFA date) for Amondys 45 + Vyondys 53 in Duchenne muscular dystrophy (conversion to traditional approval) is February 28, 2027.
Who disclosed it: Sarepta Therapeutics. The FDA does not publish these dates.
Can it move: the FDA can act early, and a major amendment to the application can push the date back 3 months.
Source: Sarepta press release
What is Amondys 45 + Vyondys 53 being reviewed for?
Sarepta Therapeutics submitted a sNDA for Amondys 45 + Vyondys 53 in Duchenne muscular dystrophy (conversion to traditional approval).
What to know: Sarepta asked the FDA to convert the accelerated approvals of Amondys 45 and Vyondys 53 to traditional approvals, citing its ESSENCE confirmatory study and real-world evidence. ESSENCE, which enrolled boys aged 6 to 13, did not show a statistically significant benefit on its main goal, how fast they climbed 4 stairs at 96 weeks, BioPharma Dive reported on November 4, 2025. Sarepta said the study was compromised by the COVID-19 pandemic. Sarepta announced on June 30, 2026 that the FDA accepted both applications. Both drugs stay available under their accelerated approvals during the review.
Is there already an FDA-approved treatment for Duchenne Muscular Dystrophy?
Yes. Trial Friend's drug list includes 8 FDA-approved drugs for Duchenne Muscular Dystrophy.
Approved: Exondys 51 (eteplirsen), Emflaza (deflazacort), Vyondys 53 (golodirsen), Viltepso (viltolarsen), Amondys 45 (casimersen), Elevidys (delandistrogene moxeparvovec), Agamree (vamorolone), Duvyzat (givinostat).
Also coming: Deramiocel.
Check: the Duchenne Muscular Dystrophy page also searches FDA drug labels for approved treatments.
Can I get Amondys 45 + Vyondys 53 before the FDA decides?
Amondys 45 + Vyondys 53 is already FDA approved for Duchenne Muscular Dystrophy. This decision is about a change to its label. Ask your doctor whether the current label already covers you.
Trials: 79 Duchenne Muscular Dystrophy studies are open or about to open. See them.
Check your fit: Match Me compares your details with every open trial.
Expanded access: your doctor can ask Sarepta Therapeutics directly. Registered programs are listed on ClinicalTrials.gov.
How much will Amondys 45 + Vyondys 53 cost?
Amondys 45 + Vyondys 53 is already sold in the US for Duchenne Muscular Dystrophy. Trial Friend does not list a price, and what you pay depends on your insurer and drugmaker help.
Find help: the patient assistance finder lists programs by insurance type.
What happens after the Amondys 45 + Vyondys 53 decision?
This page updates with the outcome the day it is announced.
If approved: the label changes. Amondys 45 + Vyondys 53 is already sold in the US for this condition, so there is no new launch to wait for.
If not approved: a complete response letter means the FDA declined the application in its current form. Many are about manufacturing or how data were presented, and companies often resubmit.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from Sarepta press release. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified daily.